Patents for A61P 35 - Antineoplastic agents (221,099)
03/2011
03/03/2011WO2011025927A1 Compounds and compositions as protein kinase inhibitors
03/03/2011WO2011025859A1 Condensed quinolines as protein kinase modulators
03/03/2011WO2011025566A1 Development of universal cancer drugs and vaccines
03/03/2011WO2011025556A1 Targeting pax2 for the treatment of breast cancer
03/03/2011WO2011025545A1 Sphingosine type 1 inhibitors and methods for making and using same
03/03/2011WO2011025167A2 Pharmaceutical composition for preventing or treating cancer comprising 2,6-substituted 3-nitropyridine derivative compound or pharmaceutically acceptable salt thereof
03/03/2011WO2011025050A1 Apoptosis inducer
03/03/2011WO2011024955A1 Nucleic acid capable of binding to tgf-βii-type receptor, and use thereof
03/03/2011WO2011024918A1 Antiangiogenic agent and method for inhibition of angiogenesis
03/03/2011WO2011024873A1 Fused heterocyclic ring derivative and use thereof
03/03/2011WO2011024872A1 Fused heterocyclic ring derivative and use thereof
03/03/2011WO2011024871A1 Fused heterocyclic ring derivative and use thereof
03/03/2011WO2011024869A1 Fused heterocyclic ring derivative and use thereof
03/03/2011WO2011024711A1 Novel compound amycolose derivative, and production process and use of same
03/03/2011WO2011024482A1 Method for measurement of ability of inducing antigen-specific t cells
03/03/2011WO2011024441A1 Ercc6l as target genes for cancer therapy and diagnosis
03/03/2011WO2011024428A1 Breast cancer related gene c12orf32
03/03/2011WO2011024156A1 Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders
03/03/2011WO2011024001A1 Np-1 antagonists and their therapeutic use
03/03/2011WO2011023989A1 Aromatase inhibitor
03/03/2011WO2011023986A1 Kinase inhibitors
03/03/2011WO2011023883A1 Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents
03/03/2011WO2011023812A1 Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
03/03/2011WO2011023773A1 Compounds and compositions as protein kinase inhibitors
03/03/2011WO2011023624A1 Bisphosphonates as inhibitors of acid sphingomyelinase
03/03/2011WO2011023390A1 Antibodies against cdcp1 for the treatment of cancer
03/03/2011WO2011023389A1 Humanized anti-cdcp1 antibodies
03/03/2011WO2011023367A2 Bisphosphonate-prodrugs
03/03/2011WO2011023146A1 Imatinib mesylate polymorphs generated by crystallization in aqueous inorganic salt solutions
03/03/2011WO2011023130A1 Anti-vegf monoclonal antibody and pharmaceutical composition comprising said antibody
03/03/2011WO2011022928A1 Quinolines compounds, their preparation methods, pharmaceutical compositions containing the same and use thereof
03/03/2011WO2011022861A1 Fulvestrant nanosphere/microsphere and preparative method and use thereof
03/03/2011WO2011022805A1 Novel colchicine derivatives, methods and uses thereof
03/03/2011WO2011022782A1 Combinations comprising imatinib mesylate and diclofenac
03/03/2011WO2011022772A1 Combination therapy for treating proliferative diseases
03/03/2011WO2011006794A8 3-oxo-2, 3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors
03/03/2011WO2011005525A3 Prodrug anti-cancer therapy
03/03/2011WO2011005377A9 Compositions and methods comprising vegfr-2 and vegfr-3 antagonists for the treatment of metastatic disease
03/03/2011WO2010148496A8 Lipidated tumor- associated antigens and immunotherapeutic compositions
03/03/2011WO2010148223A3 Anti-vegf antibodies and their uses
03/03/2011WO2010145197A8 Novel 6-arylamino pyridone sulfonamides and 6-arylamino pyrazinone sulfonamdies as mek inhibitors
03/03/2011WO2010141143A3 Engineered avirulent bacteria strains and use in medical treatments
03/03/2011WO2010132622A3 Anticd20-cpg conjugates and methods of treating b cell malignancies
03/03/2011WO2010129339A3 Compositions and methods for enhancing antigen-specific immune responses
03/03/2011WO2010129337A3 New oral formulations for tetrapyrrole derivatives
03/03/2011WO2010124283A3 Methods and compositions relating to hematologic malignancies
03/03/2011WO2010124163A3 Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
03/03/2011WO2010118347A3 O-linked glycan biosynthesis modulators
03/03/2011WO2010115092A3 Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
03/03/2011WO2010101793A3 Methods and compositions for the diagnosis, prognosis and treatment of cancer
03/03/2011WO2010098613A9 Tm7sf3 composition for diagnosing liver cancer, diagnostic kit containing anti-tm7sf3 antibodies, and pharmaceutical composition for preventing or treating liver cancer
03/03/2011WO2010028216A8 Porphyrazine optical and dual optical/mr contrast and therapeutic agents
03/03/2011WO2010002779A3 Naphthyridininones as aurora kinase inhibitors
03/03/2011WO2009016433A3 Oncolytic rhabdovirus
03/03/2011WO2009002931A3 Methods and uses thereof of prosaposin
03/03/2011WO2008035209A3 Quinoline and quinazoline derivatives as inhibitors of protein tyrosine kinase activity
03/03/2011WO2008035208A3 The use of polymethoxyflavones for the non apoptotic inhibition of cancer cell growth
03/03/2011US20110055942 Single domain TDF-related compounds and analogs thereof
03/03/2011US20110054237 Methods and Systems for Magnetic Focusing of Therapeutic, Diagnostic or Prophylactic Agents to Deep Targets
03/03/2011US20110054159 Rna interference mediating small rna molecules
03/03/2011US20110054043 Film composition
03/03/2011US20110054040 Bicyclic Triterpenoid Iripallidal as a Novel Anti-Glioma and Anti-Neoplastic Therapy
03/03/2011US20110054037 Bis-aromatic anticancer agents
03/03/2011US20110054035 Combination Comprising Combretastatin and Anticancer Agents
03/03/2011US20110054029 Water-soluble dietary fatty acids
03/03/2011US20110054023 Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
03/03/2011US20110054019 Cancer Starvation Therapy
03/03/2011US20110054018 Inotilone derivatives as coherent biological response modifier (cBMR)
03/03/2011US20110054015 Solid forms of ortataxel
03/03/2011US20110054014 Prenylflavanone compounds and uses thereof
03/03/2011US20110054012 Methods and Compositions for Increasing Gene Expression
03/03/2011US20110054009 MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders
03/03/2011US20110054006 Regulation of oncogenes by micrornas
03/03/2011US20110054005 Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
03/03/2011US20110054003 Antisense oligonucleotide modulation of stat3 expression
03/03/2011US20110054002 Alkyl indole-3-carbinol-derived antitumor agents
03/03/2011US20110054001 Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
03/03/2011US20110053999 4-methylpyrazole formulations for inhibiting ethanol intolerance
03/03/2011US20110053994 Potent immunosuppressive agents, derivatives and uses
03/03/2011US20110053993 Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
03/03/2011US20110053992 Novel Inhibitors of Proliferation and Activation of Signal Transducer and Activator of Transcription (STATS)
03/03/2011US20110053991 Treatment of Histone Deacetylase Mediated Disorders
03/03/2011US20110053986 Respiratory disease treatment
03/03/2011US20110053983 (5r)-1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives having cb1-antagonistic activity
03/03/2011US20110053977 Small molecule e2f inhibitor
03/03/2011US20110053976 Quinoline derivatives and their use as tyrosine kinase inhibitors
03/03/2011US20110053974 Carboxylic acid compound
03/03/2011US20110053973 Compounds as tyrosine kinase modulators
03/03/2011US20110053972 Inhibitors of akt activity
03/03/2011US20110053968 Aminopyrimidine inhibitors of tyrosine kinase
03/03/2011US20110053967 (poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents
03/03/2011US20110053965 Sulfonated precursors of thymidine for the treatment of epithelial hyperplasias
03/03/2011US20110053964 4-aminoquinazoline derivatives and methods of use thereof
03/03/2011US20110053963 Tartrate salts of quinazoline based egfr inhibitors containing a zinc binding moiety
03/03/2011US20110053960 Method for treating pain syndrome and other disorders
03/03/2011US20110053959 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
03/03/2011US20110053955 Anti-cytokine heterocyclic compounds
03/03/2011US20110053946 Aryl-Quinolyl Compounds and Their Use
03/03/2011US20110053944 Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
03/03/2011US20110053938 Compounds and Compositions For Treating Cancer